News

They haven't peaked yet.

Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks Making Investors Richer. Moderna extended its winning streak to a fifth consecutive day on Wednesday, climbing 11.55 percent to end at $61.80 apiece, as investors loaded their portfolios ahead of its Investor Day. In a notice, Moderna Inc. (NASDAQ:MRNA) said that it will host an Investor […]

(Updates with index/price moves, FedWatch outlook, macro data, and political/company news from the f

US equity indexes were lower on Wednesday as government bond yields rose and the Federal Reserve ann

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index falling 1.3% and

Biotech stocks climbed Wednesday after the Food and Drug Administration signaled the end of a "nail-biting journey" for UniQure.

Moderna jumps after FDA briefing documents on mFlusiva appear more constructive than expected ahead of a key advisory panel review.

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 12 Best Growth Stocks Trading in Oversold Territory. On May 20, Roivant Sciences reported its financial results for FQ4 and the full year FY2026, alongside a comprehensive business update. The company finished the year with $4.3 billion in consolidated cash and marketable securities, providing a runway into […]

Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

June Nasdaq 100 E-Mini futures (NQM26) are up +0.54% this morning, signaling a rebound from yesterday’s selloff, while investors await the first Federal Reserve rate decision under Kevin Warsh.

Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks With Standout Gains. Moderna extended its winning streak to a fourth consecutive day on Tuesday, surging 6.27 percent to close at $55.40 apiece, as investors digested the looming launch of three new vaccines over the next two years. In a statement on the same day, Moderna […]

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.1% in the afternoon session after investors positioned ahead of a pivotal FDA advisory committee review for its mRNA seasonal flu vaccine.

The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet on June 18 to assess the benefit-risk profile of mFlusiva.

Retail investors reassess growth favorites as Robinhood’s job cuts ripple through a market tilting toward industrial and financial stocks, today, June 16, 2026.

US equity indexes were mixed on Tuesday after the Dow Jones Industrial Average hit a new all-time in

Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes Moderna stock to +94% year to date (YTD), easily the best performance in the major vaccine cohort. By comparison, Pfizer (NYSE:PFE) stock is ... Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Moderna stock surged Tuesday after documents posted ahead of a key meeting suggested the FDA would likely approve its flu shot.

Highflying technology and artificial intelligence stocks are climbing early Tuesday but the rally isn't nearly as broad-based as the previous session.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

Internationally renowned for their life-saving Covid vaccine, what is Moderna doing now? Their CEO joins us in the studio to discuss bioterrorism, pandemic preparedness and cancer treatment.View on euronews

Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the 10 Most Profitable Small Cap Stocks to Buy. On May 13, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported Q1 2026 revenue of $179.1 million with estimated license revenue tied to its litigation settlement with Moderna. The company said revenue jumped from $1.8 million a year earlier because of […]

Moderna stock overview Moderna (MRNA) has drawn fresh attention after recent trading left the stock around $49.64, with returns mixed over the past week and month but well ahead year to date compared with the past 3 years. See our latest analysis for Moderna. The recent jump, with a 1-day share price return of 7.94%, comes after a period where the 30-day share price return is down 6.81% and the 3-year total shareholder return is down 61.81%, even as the 1-year total shareholder return stands...

It's important to consider your comfort with risk before diving in.

Parabilis stock soared on its Nasdaq debut, but a deeper dive suggests PBLS shares could extend gains further through the remainder of 2026.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion combined.

Moderna Is Losing Billions. Here's Why That Might Be Exactly the Right Strategy.

Genomics companies are an exciting frontier in health care, and ETFs can help to diversify to control risk while positioning investors to benefit.

In recent days, Moderna and Merck reported five-year Phase 2b data showing that their personalized mRNA melanoma vaccine intismeran autogene, combined with Keytruda, substantially reduced the risk of cancer recurrence, metastasis, and death compared with Keytruda alone. At the same time, Moderna secured up to US$50.00 million in funding from CEPI for its Bundibugyo ebolavirus mRNA vaccine candidate, underscoring how its platform is being applied to both oncology and emerging infectious...

Merck & Co., Inc. (NYSE:MRK) is one of the best cheap stocks to buy for beginners. Moderna, Inc. and Merck & Co., Inc. (NYSE:MRK) announced on June 1 detailed results from a planned five-year follow-up analysis of the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study evaluating intismeran autogene in combination with KEYTRUDA® in patients with high-risk melanoma following […]